These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7025341)

  • 1. Successful treatment of Raynaud's Syndrome with prostacyclin.
    Belch JJ; Newman P; Drury JK; Capell H; Leiberman P; James WB; Forbes CD; Prentice CR
    Thromb Haemost; 1981 Jun; 45(3):255-6. PubMed ID: 7025341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.
    Belch JJ; Newman P; Drury JK; McKenzie F; Capell H; Leiberman P; Forbes CD; Prentice CR
    Lancet; 1983 Feb; 1(8320):313-5. PubMed ID: 6130329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).
    Dowd PM; Martin MF; Cooke ED; Bowcock SA; Jones R; Dieppe PA; Kirby JD
    Br J Dermatol; 1982 Jan; 106(1):81-9. PubMed ID: 7037038
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative].
    Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP
    Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers.
    Cruz JE; Ward A; Anthony S; Chang S; Bae HB; Hermes-DeSantis ER
    Ann Pharmacother; 2016 Dec; 50(12):1060-1067. PubMed ID: 27465880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue.
    Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ
    Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of severe Raynaud syndrome in scleroderma or thromboangiitis obliterans with prostacyclin (prostaglandin I2)].
    Rüthlein HJ; Riegger G; Auer IO
    Z Rheumatol; 1991; 50(1):16-20. PubMed ID: 2058317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2)].
    Cabane J; Boue F; Godeau P; Lecompte T; Charpentier MC; Samama M; Nebout T
    Rev Med Interne; 1985 Dec; 6(5):581-9. PubMed ID: 3914023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raynaud's phenomenon in systemic lupus erythematosus.
    Lavras Costallat LT; Valente Coimbra AM
    Rev Rhum Engl Ed; 1995 May; 62(5):349-53. PubMed ID: 7655867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].
    Kumagai S; Morinobu A; Ozaki S; Nakao K; Ishida H
    Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin.
    Shawket S; Dickerson C; Hazleman B; Brown MJ
    Br J Clin Pharmacol; 1991 Aug; 32(2):209-13. PubMed ID: 1931469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raynaud's disease and prostacyclin.
    Kennerly D
    Ann Intern Med; 1983 Feb; 98(2):258. PubMed ID: 6337542
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged remission in Raynaud's phenomenon after prostacyclin infusion.
    Bellucci S; Kedra AW; Courmelle JM; Maclouf J; Boizard B; Dosquet-Bernard C; Tobelem G; Caen JP
    Scand J Rheumatol; 1986; 15(4):392-8. PubMed ID: 3547631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study of Raynaud's syndrome using dynamic infrared thermography].
    Shcherbakov AB; Koreneva LG; Markov AG
    Revmatologiia (Mosk); 1990; (2):7-11. PubMed ID: 2218268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis.
    McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ
    Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained.
    Kingma K; Wollersheim H; Thien T
    J Cardiovasc Pharmacol; 1995 Sep; 26(3):388-93. PubMed ID: 8583779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoprostenol in patients with Raynaud's disease.
    Fitscha P; Kaliman J; Weidinger F; Sinzinger H; O'Grady J
    Prostaglandins Leukot Essent Fatty Acids; 1988 Jul; 33(1):23-7. PubMed ID: 3141936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.